NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Urology: mCRPC bone-targeted therapy (radium-223, ALSYMPCA)

Free question published 19 November 2026

UrologymCRPC bone-targeted therapy (radium-223, ALSYMPCA)

A 75-year-old man with metastatic castration-resistant prostate cancer has multiple symptomatic bone metastases requiring regular analgesia. Staging shows no visceral metastases and no bulky nodal disease. He has progressed after docetaxel and abiraterone. Which treatment improves overall survival and delays symptomatic skeletal events in this bone-predominant setting?

  1. AStrontium-89
  2. BZoledronic acid alone
  3. CSamarium-153
  4. DHemibody external beam radiotherapy
  5. ERadium-223 dichloride

Why E is correct

ALSYMPCA randomised men with castration-resistant prostate cancer and symptomatic bone metastases (no visceral disease) to radium-223 or placebo. Radium-223 significantly improved overall survival and prolonged the time to the first symptomatic skeletal event. The absence of visceral metastases makes this patient an appropriate candidate.

And why the others are not

  • AIncorrect: strontium-89 is a beta-emitter used for pain palliation without a comparable proven survival benefit.
  • BIncorrect: zoledronic acid reduces skeletal events but did not provide the survival benefit demonstrated for radium-223.
  • CIncorrect: samarium-153 palliates bone pain but is not shown to prolong survival.
  • DIncorrect: hemibody radiotherapy palliates pain but is not a survival-prolonging systemic alpha-emitter.

Source ALSYMPCA — Radium-223 in mCRPC with symptomatic bone metastases — Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-223.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing